{"transactions":[{"id":4081635,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-01T16:30:28.000Z","date":"2018-01-30","kind":"exercise","acquired":false,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On April 7, 2017, the reporting person was granted 130,000 restricted stock units, all of which vested on January 30, 2018. The common stock into which such vested restricted stock units converted on January 30, 2018 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On April 7, 2017, the reporting person was granted 130,000 restricted stock units, all of which vested on January 30, 2018. The common stock into which such vested restricted stock units converted on January 30, 2018 is reported in Table I on this Form 4."}],"balance_after":150000,"derivative":{"underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0000899243-18-002485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000089924318002485/doc4.xml","form_type":"4"}},{"id":4081634,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-02-01T16:30:28.000Z","date":"2018-01-30","kind":"tax_withholding","acquired":false,"shares":62010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 62,010 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 30, 2018."}],"balance_after":842645,"source":{"system":"sec-edgar","filing":"0000899243-18-002485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000089924318002485/doc4.xml","form_type":"4"}},{"id":4081633,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-02-01T16:30:28.000Z","date":"2018-01-30","kind":"exercise","acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On April 7, 2017, the reporting person was granted 130,000 restricted stock units, all of which vested on January 30, 2018.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on April 10, 2017."}],"balance_after":904655,"source":{"system":"sec-edgar","filing":"0000899243-18-002485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000089924318002485/doc4.xml","form_type":"4"}},{"id":4089593,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2018-01-25T17:01:27.000Z","date":"2018-01-23","kind":"grant","acquired":true,"shares":662500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1412500,"derivative":{"exercise_price":0.3,"exercise_date":"2018-01-23","expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":662500},"source":{"system":"sec-edgar","filing":"0000899243-18-001902","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000089924318001902/doc4.xml","form_type":"4"}},{"id":4107138,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2018-01-04T21:03:41.000Z","date":"2018-01-02","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 2, 2017, the reporting person was granted 200,000 restricted stock units, 50,000 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 2, 2017, the reporting person was granted 200,000 restricted stock units, 50,000 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4."}],"balance_after":280000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-000546","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000089924318000546/doc4a.xml","form_type":"4/A","original_submission_date":"2018-01-04"}},{"id":4107137,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-01-04T21:03:41.000Z","date":"2018-01-02","kind":"tax_withholding","acquired":false,"shares":25487,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 25,487 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2018."}],"balance_after":774655,"source":{"system":"sec-edgar","filing":"0000899243-18-000546","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000089924318000546/doc4a.xml","form_type":"4/A","original_submission_date":"2018-01-04"}},{"id":4107136,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-01-04T21:03:41.000Z","date":"2018-01-02","kind":"exercise","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On January 2, 2017, the reporting person was granted 200,000 restricted stock units, 50,000 of which vested on January 2, 2018.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017."}],"balance_after":800142,"source":{"system":"sec-edgar","filing":"0000899243-18-000546","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000089924318000546/doc4a.xml","form_type":"4/A","original_submission_date":"2018-01-04"}},{"id":4107135,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2018-01-04T17:16:53.000Z","date":"2018-01-02","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 2, 2017, the reporting person was granted 200,000 restricted stock units, 50,000 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 2, 2017, the reporting person was granted 200,000 restricted stock units, 50,000 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4."}],"balance_after":280000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-000486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000089924318000486/doc4.xml","form_type":"4"}},{"id":4107134,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-01-04T17:16:53.000Z","date":"2018-01-02","kind":"tax_withholding","acquired":false,"shares":25487,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 25,487 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2018."}],"balance_after":769905,"source":{"system":"sec-edgar","filing":"0000899243-18-000486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000089924318000486/doc4.xml","form_type":"4"}},{"id":4107133,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-01-04T17:16:53.000Z","date":"2018-01-02","kind":"exercise","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On January 2, 2017, the reporting person was granted 200,000 restricted stock units, 50,000 of which vested on January 2, 2018.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017."}],"balance_after":795392,"source":{"system":"sec-edgar","filing":"0000899243-18-000486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000089924318000486/doc4.xml","form_type":"4"}},{"id":4230516,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2017-08-17T16:30:48.000Z","date":"2017-08-15","kind":"grant","acquired":true,"shares":745392,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Mr. Welch was granted a stock award of 745,392 shares of common stock pursuant to the Trovagene, Inc. 2014 Equity Incentive Plan which vested upon date of grant."}],"balance_after":745392,"source":{"system":"sec-edgar","filing":"0001104659-17-052470","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000110465917052470/a4.xml","form_type":"4"}},{"id":4355238,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2017-04-10T16:03:12.000Z","date":"2017-04-07","kind":"grant","acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall vest on January 30, 2018 provided that the reporting person provides continuous service to Trovagene, Inc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs shall vest on January 30, 2018 provided that the reporting person provides continuous service to Trovagene, Inc."}],"balance_after":330000,"derivative":{"underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001104659-17-022530","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000110465917022530/a4.xml","form_type":"4"}},{"id":4502140,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2017-01-04T17:01:26.000Z","date":"2017-01-02","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall vest in equal annual installments over 4 years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs shall vest in equal annual installments over 4 years."}],"balance_after":200000,"derivative":{"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001104659-17-000634","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000110465917000634/a4.xml","form_type":"4"}},{"id":4516826,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2016-12-19T13:49:29.000Z","date":"2016-12-16","kind":"purchase","acquired":true,"shares":2250,"price":2.086,"value":4693.5,"ownership":{"direct":true},"balance_after":4750,"source":{"system":"sec-edgar","filing":"0001104659-16-162787","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000110465916162787/a4.xml","form_type":"4"}},{"id":4516825,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":169887,"kind":"person","name":"WELCH WILLIAM J","position":1,"cik":"0001237522","reported_name":"WELCH WILLIAM J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2016-12-19T13:49:29.000Z","date":"2016-12-16","kind":"purchase","acquired":true,"shares":2500,"price":2.1,"value":5250.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001104659-16-162787","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237522/000110465916162787/a4.xml","form_type":"4"}}]}